TY - JOUR
T1 - Familial hypercholesterolemia mutations in the Middle Eastern and North African region
T2 - A need for a national registry
AU - Bamimore, Mary Aderayo
AU - Zaid, Ahmed
AU - Banerjee, Yajnavalka
AU - Al-Sarraf, Ahmad
AU - Abifadel, Marianne
AU - Seidah, Nabil G.
AU - Al-Waili, Khalid
AU - Al-Rasadi, Khalid
AU - Awan, Zuhier
N1 - Funding Information:
DNA testing can be funded fully or partially by patients or through partnership among academic centers, charities, and industry (including pharmaceutical). The registry charter, governing board, research, and ethics will be dictated by existing local medical societies working together with lipid specialists in academic centers. Additional funding may also come from charities and industry; many cancer and renal failure registries were supported by nongovernment funding.
Publisher Copyright:
© 2015 National Lipid Association.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Background Familial hypercholesterolemia (FH) is a well-understood Mendelian disorder that increases the risk of cardiovascular disease (CVD), a leading cause of mortality in Middle Eastern and North African (MENA) countries. Objective Review the reporting status of FH mutations across MENA and propose a systemic and strategic method for building a MENA FH registry. Methods Systematic literature search for statistics pertaining to CVD and comparison of number of FH mutations reported in MENA countries and countries with established FH registries. Results Only 57 mutations were reported in 17 MENA countries, whereas more than 500 mutations reported in 3 Western countries. Mortality rates due to CVD were significantly higher in MENA countries compared with Western countries. Conclusions The relatively low reporting of FH mutations in the consanguineous MENA communities with higher prevalence of CVD indicates poor awareness of CVD genetic risk and warrants a registry to prevent premature CVD due to FH. This registry will help in identifying novel and reported FH mutations, all of which will have clinical and research benefits in MENA countries.
AB - Background Familial hypercholesterolemia (FH) is a well-understood Mendelian disorder that increases the risk of cardiovascular disease (CVD), a leading cause of mortality in Middle Eastern and North African (MENA) countries. Objective Review the reporting status of FH mutations across MENA and propose a systemic and strategic method for building a MENA FH registry. Methods Systematic literature search for statistics pertaining to CVD and comparison of number of FH mutations reported in MENA countries and countries with established FH registries. Results Only 57 mutations were reported in 17 MENA countries, whereas more than 500 mutations reported in 3 Western countries. Mortality rates due to CVD were significantly higher in MENA countries compared with Western countries. Conclusions The relatively low reporting of FH mutations in the consanguineous MENA communities with higher prevalence of CVD indicates poor awareness of CVD genetic risk and warrants a registry to prevent premature CVD due to FH. This registry will help in identifying novel and reported FH mutations, all of which will have clinical and research benefits in MENA countries.
KW - Cardiovascular diseases
KW - Cascade testing
KW - Familial hypercholesterolemia registry
KW - Genetic screening
KW - Mutations
UR - http://www.scopus.com/inward/record.url?scp=84928824037&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928824037&partnerID=8YFLogxK
U2 - 10.1016/j.jacl.2014.11.008
DO - 10.1016/j.jacl.2014.11.008
M3 - Review article
C2 - 25911074
AN - SCOPUS:84928824037
SN - 1933-2874
VL - 9
SP - 187
EP - 194
JO - Journal of Clinical Lipidology
JF - Journal of Clinical Lipidology
IS - 2
ER -